Načítá se...
Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes
We explored the effects of the oral histone deacetylase (HDAC) inhibitor ITF2357 in patients with autoinflammatory syndrome. In this prospective open-label pilot study, eight patients were enrolled; one patient with tumor necrosis factor receptor–associated periodic syndrome (TRAPS), three patients...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
ScholarOne
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3105134/ https://ncbi.nlm.nih.gov/pubmed/21274502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2119/molmed.2011.00039 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|